CEO
Daejoong Life Science
Seoul, South Korea
I am a CEO of StarryBio which was established strategically to acquire the US phase 3 dosing completed asset for the Greater China right and the US right.
I began my career as a Korean patent attorney after graduating Seoul National University with a major of Chemical & Biological Engineering.
I spent many years in intellectual property practice as a managing partner of IP law firm based in Seoul, Korea, with a strong focus on life sciences and biotechnology.
In 2018, I founded "Daejoong Life Science", expanding my work beyond traditional IP services into strategic advisory and venture creation. Since then, I have been advising biotech and medtech companies and investors on IP strategy, licensing, fundraising, and cross-border transactions.
Currently, Daejoong Life Science got an official mandate from the original developer of TG-C, a clinical-stage knee osteoarthritis (OA) asset, for the Greater China region.
We are seeking potential licensees across Mainland China, Taiwan, Hong Kong and Macau.
In parallel, we strategically prepared a biotech, StarryBio, a newly formed NewCo, to further develop and commercialize TG-C in the Greater China region first and then other big market like the US market with further funding from global investors.
We are actively raising capital for StarryBio for commercialization of TG-C in the greater China region first and then the US later.
Project
Project for Potential Osteoarthritis Global Player
Commercialization after Acquisition of US phase 3 dosing completed asset in the territory of "China, Taiwan, Hong Kong and Macau" at first.